The pharmaceutical market in the Democratic Republic of Congo (DRC) has long been shaped by the country’s complex socio-political landscape, including decades of political instability, economic turmoil, and armed conflicts. As one of Africa’s largest and most resource-rich countries, the DRC faces significant healthcare challenges, compounded by poor infrastructure, inadequate regulatory frameworks, and limited access to essential medicines, particularly in remote regions. In response, the pharmaceutical sector has evolved, with the increasing involvement of non-governmental organizations (NGOs), international donors, and private companies.
According to various sources, the pharmaceutical market in the DRC has shown steady growth over the past decade. Key factors contributing to this include population growth, urban migration, and improved healthcare infrastructure supported by international organizations such as the Global Fund, UNICEF, and UNAIDS. In the same time, The Democratic Republic of Congo (DRC) has the second highest number of malaria cases and deaths globally.
Chapter 1: Market Growth and the Influence of International and Domestic Donors
In recent years, international partners, such as the World Health Organization (WHO), have continued to support the reform of the healthcare sector in the DRC. As a result, programs to improve the quality and availability of medicines in remote areas of the country have been launched. However, the issue of counterfeit drugs and the shortage of quality medical supplies remains pressing. Nevertheless, efforts to combat counterfeit products have led to the creation of stricter legislative measures for drug registration and quality control.
1.1 Strengthening Government Regulation
In recent years, the DRC has intensified government control over the pharmaceutical sector. One of the key structures remains the Direction de la Pharmacie et du Médicament, which continues to oversee the quality and safety of pharmaceuticals. However, despite increased oversight, corruption and insufficient coordination between government bodies remain serious issues.
As of 2023, several initiatives have been implemented in the country to centralize procurement and improve drug distribution, which were expected to reduce the level of counterfeit products in the market. One such step was the creation of the National Drug Supply System (SNAME), which helped optimize logistics and reduce delays in supply to public healthcare institutions.
1.2 The Role of Non-Governmental Organizations
Non-governmental organizations (NGOs) have continued to play a crucial role in providing medicines to remote regions. For example, Caritas Development Congo and IDA Foundation remained key players in drug delivery, especially during crises and epidemics.
1.3 Dynamics of the Private Sector
The private sector is showing growth and becoming increasingly competitive. Among the companies operating in the market are Pharmagros and Prince Pharma, which have continued to expand their product range. However, since the 2020s, new players have emerged in the market.
In recent years, several major international pharmaceutical companies have entered the DRC market, linked to improvements in the country’s investment climate and government support for healthcare development programs. Notable new companies include Sanofi, GlaxoSmithKline, PharmaKin, and Unichem Congo, as well as Indian and Chinese companies like Cipla and Sinopharm. These companies not only supply medicines but also implement educational programs on the use of their products.
Additionally, PharmaCongo, established in 2014, is actively involved in the import and distribution of pharmaceuticals, particularly in Kinshasa and other major cities. The company focuses on providing affordable generics. MedAfrik, established in 2017, has become one of the key players in the distribution of medical equipment and supplies, with their products being especially sought after in remote areas of the country. These companies have played a significant role in increasing the availability of medicines and reducing dependency on imports from India and China.
| PRODUCT | FORMULA | MANUFACTURER | PRICE (USD) | PRICE (USD) – 2023 |
| PALUCUR | Dihydroartemisinin- Piperaquine Phosphate | Pharmagros, DRC | 5.20 | 6.50 |
| CETHER – L | Artemether – Lumefantrine | New Cesamex, DRC | 4.70 | 6.00 |
| LONART – DS | Artemether – Lumefantrine | Bliss GVS Pharma Ltd, India | 5.75 | 7.30 |
| ARTE-PLUS | Artesunate-Sufalene- Pyrimethamine | KIM-Pharma, DRC (licensed by COLIFE, South Korea) | 4.30 | 5.60 |
| LUTHER DP | Artemether – Lumefantrine | Zest Pharma, India | 5.00 | 6.90 |
| MALAXIN-PLUS | Dihydroartemisinin – Sufalene – Pyrimethamine | KIM-Pharma, DRC (licensed by COLIFE, South Korea) | 4.30 | 5.50 |
| DIPERAKINE | Dihydroartemisinin – Piperaquine Phosphate | Pharbaco Central Pharmaceutical, Vietnam | 3.40 | 4.50 |
| CO-RIMETAR | Artemether – Lumefantrine | Alisons, Belgium | 3.50 | 4.80 |
| LONART FORTE | Artemether – Lumefantrine | Bliss GVS Pharma Ltd, India | 5.50 | 7.00 |
1. The prices of all anti-malarial products have increased in the past decade, reflecting inflation and possibly other market factors like supply chain disruptions.
2. Drugs manufactured locally in the DRC (e.g., KIM-Pharma and Pharmagros) have seen relatively moderate increases compared to those imported from India or other countries.
3. Consumer preferences, which may be tied to efficacy, side effects, or availability, seem consistent over time with locally produced and well-established brands still highly rated.
Chapter 2: Major Challenges
Despite positive changes, the pharmaceutical market in the DRC still faces several challenges:
- Corruption: Corruption issues continue to undermine efforts to reform the sector.
- Counterfeit Products: Although the level of counterfeit products in the market has decreased, it remains significant.
- Economic Instability: Political instability and economic issues continue to hinder the growth of the pharmaceutical sector.
2.1 Combating Epidemics
From 2018 to 2020, the DRC faced several epidemics, including Ebola and COVID-19. In response, the pharmaceutical sector received substantial support from international organizations and focused on the availability of vaccines and antiviral drugs. For example, Johnson & Johnson actively supplied Ebola vaccines as part of the WHO program.
2.2 Development of Local Production
In an effort to stimulate local drug production, several new local pharmaceutical enterprises emerged in the 2020s. One of the most notable is PharmaCongo, which opened its manufacturing facilities in 2018. Local production remains limited, but the DRC government is actively working to increase the market share of domestic producers.
2.3 Strengthening Regulatory Measures
Due to ongoing issues with counterfeit drugs, the DRC government has begun to more strictly control the import of pharmaceutical products and the licensing of companies. Enhanced quality control measures have led to improved market transparency and increased access to quality medicines for the population.
Conclusion
The pharmaceutical market in the DRC remains attractive to investors due to its significant growth potential. In the coming years, further development of the private sector, the emergence of new companies, and improvements in the regulatory system are expected, especially with international support.
The pharmaceutical market in the Democratic Republic of Congo (DRC) remains a complex and challenging environment, shaped by both long-standing issues and new opportunities. Over the past decade, there has been a noticeable shift in the sector, driven by an increasing presence of private manufacturers, international organizations, and a government more open to reform. Key challenges from the early 2010s, such as corruption, bureaucratic inefficiencies, and the distribution of counterfeit medicines, have persisted to some degree but are increasingly met with modern solutions.
New pharmaceutical companies, such as PharmaKin and Unichem Congo, have emerged in the last decade, contributing to a more dynamic private sector that is able to meet growing demands for essential medicines. The involvement of these companies has alleviated some of the pressure on the public sector, which still faces significant challenges, including weak supply chains and limited access to remote regions.
However, despite these improvements, many structural challenges remain. Corruption, political instability, and the lack of regulatory enforcement continue to deter large-scale foreign investment and create hurdles for smaller local manufacturers. Furthermore, the economic situation in the DRC remains fragile, limiting both public and private efforts to reform the healthcare system effectively.
International partnerships, particularly with organizations such as the World Health Organization (WHO) and Caritas Development Congo, remain critical. These partnerships have played a vital role in bringing in essential drugs and addressing healthcare needs in underserved areas, including remote and conflict-affected regions. In addition, international aid programs focusing on health reforms have laid the foundation for more robust public health policies and infrastructure.
Looking ahead, the future of the DRC’s pharmaceutical sector will largely depend on the government’s ability to implement meaningful reforms. Continued efforts to modernize the public health system, reduce corruption, and streamline regulations will be essential for further growth. Furthermore, the development of local pharmaceutical production will be crucial to ensuring long-term access to affordable, high-quality medications for the Congolese people.
For international investors, the DRC represents both significant challenges and substantial opportunities. Companies that can effectively navigate the political and economic risks by forming strategic partnerships with local stakeholders and understanding the regulatory environment stand to benefit from the country’s vast market potential.
Ultimately, the Congolese pharmaceutical market offers a case study in resilience, where decades of hardship and instability have created space for innovative solutions and partnerships. The coming years will be crucial in determining whether the country can continue on its path towards a more stable, well-regulated pharmaceutical industry that better meets the needs of its population.
Special thanks to the team at Assettracing.com for their valuable input in research capacities, advice, and support with resources in preparing these articles.
© 2024 United Action Foundation. All rights reserved. This publication may not be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the United Action Foundation, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.